Lundbeck A/S (Lundbeck) and Prexton Therapeutics BV (Prexton) announced the signing of a definitive agreement in which Lundbeck will acquire Prexton. Under terms of the agreement, Lundbeck will pay €100m upfront and is furthermore required to later pay up to €805m in development and sales milestones to the group of current owners.

VISCHER advised Lundbeck as lead-counsel in this transaction. The team was led by Corporate partners Christian Wyss and Robert Bernet and included Luzius Zumstein, Gian Caprez, Gian Geel, Aron Waltuch (all Corporate), Marc Prinz (Employment) and Eric Flückiger (Tax).